FI944847A - Förfarande och kompositioner för övervakning av bearbetningen av (beta)-amyloidprekursorprotein i cellen - Google Patents

Förfarande och kompositioner för övervakning av bearbetningen av (beta)-amyloidprekursorprotein i cellen Download PDF

Info

Publication number
FI944847A
FI944847A FI944847A FI944847A FI944847A FI 944847 A FI944847 A FI 944847A FI 944847 A FI944847 A FI 944847A FI 944847 A FI944847 A FI 944847A FI 944847 A FI944847 A FI 944847A
Authority
FI
Finland
Prior art keywords
beta
monitoring
amyloid
precursor protein
app
Prior art date
Application number
FI944847A
Other languages
English (en)
Finnish (fi)
Other versions
FI944847A0 (sv
FI111546B (sv
Inventor
Peter A Seubert
Dale B Schenk
Lawrence C Fritz
Original Assignee
Athena Neurosciences Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI944847(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athena Neurosciences Inc, Lilly Co Eli filed Critical Athena Neurosciences Inc
Publication of FI944847A publication Critical patent/FI944847A/sv
Publication of FI944847A0 publication Critical patent/FI944847A0/sv
Application granted granted Critical
Publication of FI111546B publication Critical patent/FI111546B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
FI944847A 1992-04-15 1994-10-14 In vitro-förfarande för övervakning av bearbetning av ett beta-amyloidföregångarprotein i celler, för diagnostisering eller övervakning av ett till beta-amyloid hänförd sjukdom eller för identifieringav inhibitorer av beta-amyloidproduktionen samt lösligt fragment av beta-amyloidföregångarprotein FI111546B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US86894992A 1992-04-15 1992-04-15
US86894992 1992-04-15
US07/965,971 US5441870A (en) 1992-04-15 1992-10-26 Methods for monitoring cellular processing of β-amyloid precursor protein
US96597192 1992-10-26
PCT/US1993/001817 WO1993021526A1 (en) 1992-04-15 1993-03-03 METHODS AND COMPOSITIONS FOR MONITORING CELLULAR PROCESSING OF β-AMYLOID PRECURSOR PROTEIN
US9301817 1993-03-03

Publications (3)

Publication Number Publication Date
FI944847A true FI944847A (sv) 1994-10-14
FI944847A0 FI944847A0 (sv) 1994-10-14
FI111546B FI111546B (sv) 2003-08-15

Family

ID=27128086

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944847A FI111546B (sv) 1992-04-15 1994-10-14 In vitro-förfarande för övervakning av bearbetning av ett beta-amyloidföregångarprotein i celler, för diagnostisering eller övervakning av ett till beta-amyloid hänförd sjukdom eller för identifieringav inhibitorer av beta-amyloidproduktionen samt lösligt fragment av beta-amyloidföregångarprotein

Country Status (14)

Country Link
US (3) US5441870A (sv)
EP (1) EP0638172B1 (sv)
JP (2) JP3974168B2 (sv)
AT (1) ATE251304T1 (sv)
AU (1) AU688726B2 (sv)
CA (1) CA2118243C (sv)
DE (1) DE69333225T2 (sv)
DK (1) DK0638172T3 (sv)
ES (1) ES2206455T3 (sv)
FI (1) FI111546B (sv)
NO (1) NO320067B1 (sv)
NZ (1) NZ251053A (sv)
PT (1) PT638172E (sv)
WO (1) WO1993021526A1 (sv)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5837672A (en) * 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
WO1994010569A1 (en) * 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
PT730643E (pt) * 1993-10-27 2001-06-29 Lilly Co Eli Animais transgenicos portadores do alelo de app com mutacao sueca
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
JPH11506923A (ja) * 1995-06-06 1999-06-22 アセナ ニューロサイエンシーズ，インコーポレイテッド 新しいカテプシンならびにその阻害のための方法および組成物
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6136530A (en) * 1995-11-29 2000-10-24 Texas Tech University Health Sciences Center Compositions and methods for assessing risk factors in Alzheimer's disease
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
JPH09178743A (ja) * 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
EP1032435B1 (en) * 1997-10-31 2003-09-03 Children's Medical Center Corporation Bladder reconstruction
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20040167634A1 (en) * 1999-05-26 2004-08-26 Anthony Atala Prosthetic kidney and its use for treating kidney disease
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7119085B2 (en) 2000-03-23 2006-10-10 Elan Pharmaceuticals, Inc. Methods to treat alzheimer's disease
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US7034182B2 (en) * 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
FR2816411B1 (fr) * 2000-11-03 2003-07-04 Inst Nat Sante Rech Med Moyens de detection de la transformation pathologique de la proteine app et leurs applications
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20030215896A1 (en) * 2001-04-25 2003-11-20 Yueming Li Gamma secretase substrates and in vitro assays
ES2312569T3 (es) * 2001-04-30 2009-03-01 Eli Lilly And Company Anticuerpos humanizados.
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
AU2002314914A1 (en) * 2001-06-01 2002-12-16 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
MXPA03011521A (es) 2001-06-13 2004-03-18 Elan Pharm Inc Aminadioles para tratamiento de enfermedad de alzheimer.
US6982264B2 (en) * 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
MXPA04000338A (es) * 2001-07-10 2004-07-23 Upjohn Co Diamindioles para tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) * 2001-07-10 2004-07-23 Upjohn Co Amindioles para tratamiento de enfermedad de alzheimer.
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
CN1658852A (zh) * 2001-08-31 2005-08-24 神经化学（国际）有限公司 用于治疗淀粉样变性的脒衍生物
BR0213139A (pt) * 2001-10-04 2004-08-10 Elan Pharm Inc Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
IL161881A0 (en) 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
BR0214217A (pt) * 2001-11-16 2004-09-21 Childrens Medical Center Aumento de função de órgão
MXPA04004713A (es) * 2001-11-19 2005-08-16 Pharmacia & Up John Company Ll Aminoides utiles en el tratamiento de la enfermedad de alzheimer.
US20050214763A1 (en) * 2002-02-14 2005-09-29 Rainer Hipfel Diagnostic and therapeutic use of an activator protein for vesicle secretion for neurodegenerative diseases
DE60303360T2 (de) * 2002-02-14 2006-09-21 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung des caps
WO2003072041A2 (en) * 2002-02-27 2003-09-04 Merck & Co., Inc. Assays to monitor amyloid precursor protein processing
AU2003225636A1 (en) * 2002-03-05 2003-09-22 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1575482A2 (en) * 2002-04-17 2005-09-21 Pharmacia & Upjohn Company LLC Compositions and method of treating alzheimer's disease
AU2003303141A1 (en) * 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
WO2004032868A2 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
KR100520495B1 (ko) * 2002-10-23 2005-10-11 한국과학기술연구원 베타아밀로이드 특이 단일 클론 항체 및 그의 제조방법
US7351738B2 (en) 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
MXPA05011150A (es) * 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
CL2004000848A1 (es) * 2003-04-21 2005-01-28 Elan Pharmaceuticals Inc Pharm Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
EP1631561B1 (en) * 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1729755A1 (en) * 2004-01-21 2006-12-13 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using aspartyl-protease inihibitors
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
US20050239832A1 (en) * 2004-03-09 2005-10-27 Varghese John Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
EP1735293A2 (en) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528400A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
EP1734942A1 (en) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
AU2005265354A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
EP1773756A2 (en) * 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
JP5042828B2 (ja) * 2004-07-30 2012-10-03 ライナット ニューロサイエンス コーポレイション アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
EP1802574A2 (en) * 2004-08-27 2007-07-04 Elan Pharmaceuticals Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
AU2006203819A1 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1913017A1 (en) * 2005-08-03 2008-04-23 Boehringer Ingelheim International GmbH Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
JP2009511589A (ja) * 2005-10-12 2009-03-19 エラン ファーマシューティカルズ，インコーポレイテッド アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) * 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) * 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20070292895A1 (en) * 2006-05-19 2007-12-20 Xiao-Ping Shi Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
CA2653628C (en) * 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100203044A1 (en) * 2006-12-22 2010-08-12 Anatoly Nikolaev Dr6 antagonists and uses thereof in treating neurological disorders
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
BRPI0810118A8 (pt) * 2007-04-18 2015-09-29 Janssen Alzheimer Immunotherap Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
US20080277393A1 (en) * 2007-05-07 2008-11-13 True Charles W Collapsible, stackable, semi-rigid universal cotainer for hazardous and non-hazardous goods
MX2009012608A (es) * 2007-05-25 2009-12-07 Amgen Inc Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
WO2008147547A1 (en) 2007-05-25 2008-12-04 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
ES2725502T3 (es) * 2007-06-08 2019-09-24 Univ Wake Forest Health Sciences Terapia celular selectiva para el tratamiento de la insuficiencia renal
US10590391B2 (en) * 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PT2170389E (pt) * 2007-06-12 2015-02-10 Genentech Inc Anticorpos humanizados contra amilóide beta
CA2692604A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US7803809B2 (en) * 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
CA2726118A1 (en) * 2008-06-12 2009-12-17 Anatoly Nikolaev Method for screening for compounds that inhibit neurodegeneration
WO2010030954A1 (en) * 2008-09-11 2010-03-18 Amgen Inc. Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2010046332A1 (en) * 2008-10-20 2010-04-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057015A1 (en) * 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
CA2744043A1 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
RU2012124093A (ru) * 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков
EP2504315A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US8822485B2 (en) 2009-11-23 2014-09-02 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2788363A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
JP2013522305A (ja) 2010-03-15 2013-06-13 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのスピロ−四環式環化合物
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
WO2012109165A1 (en) 2011-02-07 2012-08-16 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP2811018B1 (en) * 2012-02-03 2017-03-22 Shionogi & Co., Ltd. ANTI-sAPPß ANTIBODY
US9556135B2 (en) 2012-10-12 2017-01-31 Amgen, Inc. Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014120658A1 (en) 2013-01-29 2014-08-07 Amgen Inc. Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2015017407A1 (en) 2013-07-30 2015-02-05 Amgen Inc. Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase
MX2017001794A (es) 2014-08-08 2017-06-29 Amgen Inc Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
EP3070096A1 (en) * 2015-03-19 2016-09-21 Ludwig-Maximilians-Universität München A peptide or collection of peptides derived from amyloid precursor protein
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MX2019007104A (es) 2016-12-15 2019-11-05 Amgen Inc Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
JP7159161B2 (ja) 2016-12-15 2022-10-24 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのシクロプロピル縮合チアジン誘導体および使用方法
US11548903B2 (en) 2016-12-15 2023-01-10 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) * 1985-10-28 1987-05-09 Teijin Ltd 遺伝子断片およびプラスミド
WO1987002671A1 (en) * 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
EP0331514A3 (en) * 1988-03-04 1991-07-10 Ajinomoto Co., Inc. Assaying the duchenne muscular dystrophy protein deletion or defect
US5134062A (en) * 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU8215391A (en) * 1990-06-29 1992-01-23 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein

Also Published As

Publication number Publication date
PT638172E (pt) 2004-02-27
US5441870A (en) 1995-08-15
ATE251304T1 (de) 2003-10-15
DE69333225D1 (de) 2003-11-06
AU3782793A (en) 1993-11-18
AU688726B2 (en) 1998-03-19
NO943912L (no) 1994-11-10
FI944847A0 (sv) 1994-10-14
ES2206455T3 (es) 2004-05-16
JP3974168B2 (ja) 2007-09-12
JP2006051029A (ja) 2006-02-23
CA2118243A1 (en) 1993-10-28
DE69333225T2 (de) 2004-05-06
US6018024A (en) 2000-01-25
NO943912D0 (no) 1994-10-14
EP0638172A1 (en) 1995-02-15
FI111546B (sv) 2003-08-15
WO1993021526A1 (en) 1993-10-28
NZ251053A (en) 1996-11-26
EP0638172B1 (en) 2003-10-01
EP0638172A4 (en) 1997-03-19
CA2118243C (en) 2009-11-03
DK0638172T3 (da) 2004-02-02
NO320067B1 (no) 2005-10-17
US5721130A (en) 1998-02-24
JPH07506967A (ja) 1995-08-03

Similar Documents

Publication Publication Date Title
FI944847A0 (sv) Förfarande och kompositioner för övervakning av bearbetningen av (beta)-amyloidprekursorprotein i cellen
CA2174632A1 (en) Methods of screening for beta-amyloid peptide production inhibitors
Steinert et al. Initiation of assembly of the cell envelope barrier structure of stratified squamous epithelia
Kreil et al. Stepwise cleavage of the pro part of Promelittin by dipeptidylpeptidase IV: evidence for a new type of precursor—product conversion
Gross Aspects of the animal collagenases
IL141774A0 (en) Monitoring methods using particle delivery methods
PT83255A (en) Process for the preparation of polypeptides and characteristic antibodies of papillomavirus and diagnostic method thereto
KR101376471B1 (ko) 디펩티딜 펩티다제-관련 질병 상태의 진단 및 예후
Kreil Biosynthesis of Melittin, a Toxic Peptide from Bee Venom: Amino‐Acid Sequence of the Precursor
WO2000043493A8 (en) Metalloproteinase adam 22
CA2004819A1 (en) Immune cell proliferation inhibitors
WO2003008635A2 (en) η-SECRETASE IN VITRO SCREENING ASSAY
Henry et al. Co‐operation between metastatic tumor cells and macrophages in the degradation of basement membrane (type IV) collagen
Kitabchi et al. Properties of Proinsulin and Related Polypeptide
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
Salokangas et al. Bovine proinsulin: amino acid sequence of the C‐peptide isolated from pancreas
Iversen et al. The psoriasis-associated antigen, pso p27, is expressed by tryptase-positive cells in psoriatic lesions
Murray et al. Synthesis of proteolipid protein by yeast mitochondria
Chauvet et al. Divergent neuropeptide evolutionary drifts between American and Australian marsupials
Brown et al. Studies on the substrate specificity of an Escherichia coli peptidase
DAVIDSON et al. Procollagen Processing: Limited Proteolysis of COOH‐Terminal Extension Peptides by a Cathepsin‐Like Protease Secreted by Tendon Fibroblasts
Nichols et al. Glucocorticoid-induced proteins in bovine endothelial cells
Neblock et al. The proteinase inhibitors leupeptin, pepstatin A, and TLCK cause reduced collagen production in freshly isolated embryonic chick fibroblasts in suspension culture
WO2002033127A3 (en) Method for assessing recoding in vitro and in vivo
Camier et al. Synthesis and processing of pro-ocytocin in bovine corpus luteum and granulosa cells

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ELI LILLY AND COMPANY

Free format text: ELI LILLY AND COMPANY

Owner name: ELAN PHARMACEUTICALS, INC.

Free format text: ELAN PHARMACEUTICALS, INC.

MA Patent expired